Page 39 - GTM-3-1

Global Translational Medicine Immune response in humans due to COVID-19 infection

J Clin Lab Anal. 2023;37(7):e24881. 43. Fantini J, Yahi N, Colson P, Chahinian H, La Scola B,
Raoult D. The puzzling mutational landscape of the SARS‐2‐
doi: 10.1002/jcla.24881
variant Omicron. J Med Virol. 2022;94(5):2019-2025.
33. Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype
and kinetics of SARS-CoV-2-specific T cells in COVID-19 doi: 10.1002/jmv.27577
patients with acute respiratory distress syndrome. Sci 44. Goutam Mukherjee A, Ramesh Wanjari U, Murali R, et al.
Immunol. 2020;5(48):eabd2071. Omicron variant infection and the associated immunological
scenario. Immunobiology. 2022;227(3):152222.
doi: 10.1126/sciimmunol.abd2071
doi: 10.1016/j.imbio.2022.152222
34. Geng J, Chen L, Yuan Y, et al. CD147 antibody specifically
and effectively inhibits infection and cytokine storm of 45. May DH, Rubin BE, Dalai SC, et al. Immunosequencing and
SARS-CoV-2 and its variants Delta, Alpha, Beta, and epitope mapping reveal substantial preservation of the T cell
Gamma. Signal Transduct Target Ther. 2021;6(1):347. immune response to Omicron generated by SARS-CoV-2
vaccines. medRxiv. 2021.
doi: 10.1038/s41392-021-00760-8
doi: 10.1101/2021.12.20.21267877
35. Berke G. The CTL’s kiss of death. Cell. 1995;81(1):9-12.
46. Keeton R, Tincho MB, Ngomti A, et al. T cell responses
doi: 10.1016/0092-8674(95)90365-8
to SARS-CoV-2 spike cross-recognize Omicron. Nature.
36. Zhang Y, Chen Y, Li Y, et al. The ORF8 protein of SARS-CoV-2 2022;603(7901):488-492.
mediates immune evasion through down-regulating MHC-Ι. doi: 10.1038/s41586-022-04460-3
Proc Natl Acad Sci U S A. 2021;118(23):e2024202118.
47. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell
doi: 10.1073/pnas.2024202118 epitopes: Adaptive immune response against COVID-19.
37. Chaudhari AM, Singh I, Joshi M, Patel A, Joshi C. Defective Cell Host Microbe. 2021;29(7):1076-1092.
ORF8 dimerization in SARS-CoV-2 delta variant leads to doi: 10.1016/j.chom.2021.05.010
a better adaptive immune response due to abrogation of
ORF8-MHC1 interaction. Mol Divers. 2023;27(1):45-57. 48. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to
the SARS-CoV-2 Omicron variant is preserved in most but
doi: 10.1007/s11030-022-10405-9 not all individuals. Cell. 2022;185(6):1041-1051.e6.
38. Augusto DG, Hollenbach JA. HLA variation and antigen doi: 10.1016/j.cell.2022.01.029
presentation in COVID-19 and SARS-CoV-2 infection.
Curr Opin Immunol. 2022;76:102178. 49. Barros-Martins J, Hammerschmidt SI, Morillas Ramos G,
et al. Omicron infection-associated T-and B-cell immunity
doi: 10.1016/j.coi.2022.102178 in antigen-naive and triple-COVID-19-vaccinated
39. Dhawan M, Saied AA, Emran TB, Choudhary OP. individuals. Front Immunol. 2023;14:1166589.
Emergence of Omicron variant’s sublineages BA.4 and doi: 10.3389/fimmu.2023.1166589
BA.5: Risks assessment and possible countermeasures. New
Microbes New Infect. 2022;48:100997. 50. Perugino CA, Liu H, Feldman J, et al. Preferential expansion
upon boosting of cross-reactive “pre-existing” switched
doi: 10.1016/j.nmni.2022.100997 memory B cells that recognize the SARS-CoV-2 Omicron
40. Schountz T, Baker ML, Butler J, Munster V. Immunological variant Spike protein. medRxiv. 2022.
control of viral infections in bats and the emergence of doi: 10.1101/2021.12.30.21268554
viruses highly pathogenic to humans. Front Immunol.
2017;8:1098. 51. Varea-Jiménez E, Cano EA, Vega-Piris L, et al. Comparative
severity of COVID-19 cases caused by Alpha, Delta or
doi: 10.3389/fimmu.2017.01098 Omicron SARS-CoV-2 variants and its association with
41. Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, vaccination. Enferm Infecc Microbiol Clín (Engl Ed).
Wilairatana P. Omicron variant (B.1.1.529) and its 2022:S2529-993X(23)00039-4.
sublineages: What do we know so far amid the emergence doi: 10.1016/j.eimce.2022.11.021
of recombinant variants of SARS-CoV-2? Biomed 52. Dhawan M, Sharma A, Priyanka N, Thakur N, Rajkhowa TK,
Pharmacother. 2022;154:113522.
Choudhary OP. Delta variant (B.1.617.2) of SARS-CoV-2:
doi: 10.1016/j.biopha.2022.113522 Mutations, impact, challenges and possible solutions. Hum
42. Wei C, Shan KJ, Wang W, Zhang S, Huan Q, Qian W. Vaccin Immunother. 2022;18(5):2068883.
Evidence for a mouse origin of the SARS-CoV-2 Omicron doi: 10.1080/21645515.2022.2068883
variant. J Genet Genomics. 2021;48(12):1111-1121.
53. Meng B, Kemp SA, Papa G, et al. Recurrent emergence of
doi: 10.1016/j.jgg.2021.12.003 SARS-CoV-2 spike deletion H69/V70 and its role in the

Volume 3 Issue 1 (2024) 9 https://doi.org/10.36922/gtm.2228